awmsg logo



vildagliptin (Galvus®)


Reference No. 1531

Publication date:
22/03/2013


Appraisal information

vildagliptin (Galvus®) 50 mg tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Endocrine system
NMG meeting date: 09/01/2013
AWMSG meeting date: 06/02/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0213
Ministerial ratification: 18/03/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Vildagliptin (Galvus®) is recommended as an option for use within NHS Wales for the treatment of type 2 diabetes mellitus as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download